Literature DB >> 15231841

Binding of xanthine oxidase to glycosaminoglycans limits inhibition by oxypurinol.

Eric E Kelley1, Andrés Trostchansky, Homero Rubbo, Bruce A Freeman, Rafael Radi, Margaret M Tarpey.   

Abstract

Although the binding of xanthine oxidase (XO) to glycosaminoglycans (GAGs) results in significant alterations in its catalytic properties, the consequence of XO/GAG immobilization on interactions with clinically relevant inhibitors is unknown. Thus, the inhibition kinetics of oxypurinol for XO was determined using saturating concentrations of xanthine. When XO was bound to a prototypical GAG, heparin-Sepharose 6B (HS6B-XO), the rate of inactivation for uric acid formation from xanthine was less than that for XO in solution (k(inact) = 0.24 versus 0.39 min(-1)). Additionally, the overall inhibition constant (K(i)) of oxypurinol for HS6B-XO was 2-5-fold greater than for free XO (451 versus 85 nm). Univalent electron flux (O(2)(.) formation) was diminished by the binding of XO to heparin from 28.5% for free XO to 18.7% for GAG-immobilized XO. Similar to the results obtained with HS6B-XO, the binding of XO to bovine aortic endothelial cells rendered the enzyme resistant to inhibition by oxypurinol, achieving approximately 50% inhibition. These results reveal that GAG immobilization of XO in both HS6B and cell models substantially limits oxypurinol inhibition of XO, an event that has important relevance for the use of pyrazolo inhibitors of XO in clinical situations where XO and its products may play a pathogenic role.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231841     DOI: 10.1074/jbc.M402077200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Xanthine Oxidoreductase Function Contributes to Normal Wound Healing.

Authors:  Michael C Madigan; Ryan M McEnaney; Ankur J Shukla; Guiying Hong; Eric E Kelley; Margaret M Tarpey; Mark Gladwin; Brian S Zuckerbraun; Edith Tzeng
Journal:  Mol Med       Date:  2015-04-14       Impact factor: 6.354

2.  Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor raloxifene: implications for identifying molybdopterin nitrite reductases.

Authors:  E R Weidert; S O Schoenborn; N Cantu-Medellin; K V Choughule; J P Jones; E E Kelley
Journal:  Nitric Oxide       Date:  2014-01-07       Impact factor: 4.427

3.  Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy.

Authors:  Stephan Baldus; Kai Müllerleile; Phil Chumley; Daniel Steven; Volker Rudolph; Gunnar K Lund; Hans-Jürgen Staude; Alexander Stork; Ralf Köster; Jan Kähler; Christian Weiss; Thomas Münzel; Thomas Meinertz; Bruce A Freeman; Thomas Heitzer
Journal:  Free Radic Biol Med       Date:  2006-07-15       Impact factor: 7.376

4.  Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.

Authors:  Umair Z Malik; Nicholas J Hundley; Guillermo Romero; Rafael Radi; Bruce A Freeman; Margaret M Tarpey; Eric E Kelley
Journal:  Free Radic Biol Med       Date:  2011-04-15       Impact factor: 7.376

Review 5.  Xanthine oxidoreductase-catalyzed reduction of nitrite to nitric oxide: insights regarding where, when and how.

Authors:  Nadiezhda Cantu-Medellin; Eric E Kelley
Journal:  Nitric Oxide       Date:  2013-02-27       Impact factor: 4.427

6.  Hydrogen peroxide is the major oxidant product of xanthine oxidase.

Authors:  Eric E Kelley; Nicholas K H Khoo; Nicholas J Hundley; Umair Z Malik; Bruce A Freeman; Margaret M Tarpey
Journal:  Free Radic Biol Med       Date:  2009-11-24       Impact factor: 7.376

7.  Lowering serum urate does not improve endothelial function in patients with type 2 diabetes.

Authors:  W S Waring; J A McKnight; D J Webb; S R J Maxwell
Journal:  Diabetologia       Date:  2007-10-10       Impact factor: 10.122

8.  Xanthine oxidase injurious response in acute joint injury.

Authors:  Thomas Stabler; Robert D Zura; Ming-Feng Hsueh; Virginia B Kraus
Journal:  Clin Chim Acta       Date:  2015-09-28       Impact factor: 3.786

Review 9.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Adipose tissue-derived free fatty acids initiate myeloid cell accumulation in mouse liver in states of lipid oversupply.

Authors:  Daniel B Harmon; Chao Wu; Nikolaos Dedousis; Ian J Sipula; Maja Stefanovic-Racic; Gabriele Schoiswohl; Christopher P O'Donnell; Laura C Alonso; Erin E Kershaw; Eric E Kelley; Robert M O'Doherty
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-08-07       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.